药石科技：当前，管理层正全力以赴聚焦主营业务发展

Core Viewpoint - The company emphasizes that solid operating performance and sustained growth are fundamental to enhancing intrinsic value, with management focusing on core business development and implementing various measures to achieve this [1]. Group 1: Business Strategy - The current strategic focus is on deepening cooperation with large multinational pharmaceutical companies to optimize the customer structure [1]. - Revenue from MNC clients is expected to show significant growth by the third quarter of 2025, with an overall stabilization in gross margin and a substantial improvement in operating cash flow [1]. Group 2: Innovation and Efficiency - The company aims to systematically build long-term pricing power through green and intelligent chemical technology innovations, deepening customer relationships, focusing on high-value new molecular businesses such as peptides and ADCs, and enhancing operational efficiency [1]. Group 3: Market Communication and Value Management - In terms of market value management, the company will strengthen communication with the market through information disclosure and investor relations management [1]. - The company will prudently evaluate various measures, including share buybacks, equity incentives, and mergers and acquisitions, to enhance company quality and intrinsic value, and will announce any significant matters that meet disclosure standards in a timely manner [1].